Boehringer Ingelheim has launched a new artificial intelligence (AI) and machine learning (ML) center in London. This represents the company’s latest move to drive improved patient outcomes through the application of technology.
As part of Boehringer’s £150 million ($202.7 million) 10-year investment in AI across research and development, the life sciences giant expects its latest computer innovation site to lead to improved understanding of biology and identification of biological mechanisms that drive patient outcomes with higher rates of success.
Discover effective B2B marketing
We combine business intelligence and editorial excellence to reach passionate professionals across 36 major media platforms.
learn more
The company, which joins Boehringer’s existing AI-focused locations in the US, Austria and Germany, said the King’s Cross, London location will enable it to “move faster” and “make smarter decisions” when delivering new treatments to patients with unmet medical needs.
Achieving this goal will include developing fundamental AI approaches to understand patient progression, discover biological mechanisms that promote patient outcomes, and identify key causes of disease in order to discover and develop targeted medicines, Boehringer added.
With the official opening of the new site today (April 20), Boehringer expects to have its first 50 AI experts in place by the end of 2027.
Paola Casarosa, Global Head of Innovation at Boehringer Ingelheim, commented: “Establishing a presence in London will allow us to leverage the UK’s rich data resources and infrastructure, while connecting with world-class talent across academia, biotech and AI ecosystems to innovate for the benefit of patients.”
London Cancer Hub announced a $1 billion expansion of its Sutton-based site in February 2026, and Boehringer’s new site should resonate with London’s ambitions to become a global life sciences hub. Meanwhile, Boehringer’s investment in the UK could bring further relief to the sector following US pharmaceutical giant MSD’s decision to scrap its £1bn UK expansion plans in September 2025, citing dissatisfaction with the UK government’s investment in pharmaceuticals and wider life sciences.
Commenting on the launch of Boehringer’s website, UK Science Secretary Sir Patrick Vallance said: “AI is opening up opportunities to advance life science discoveries like never before, and Boehringer’s decision to open a new hub in King’s Cross will enable both companies to access and contribute to London’s thriving hub of innovation.”
